Association of vascular and inflammatory markers with metabolic disorders in women with polycystic ovary syndrome

Aleksandra Atanasova Boshku; Daniela Ivanova Panova; Beti Zafirova Ivanovska

doi:10.2298/VSP170504158B

Aleksandra Atanasova Boshku University Clinic of Obstetrics and Gynecology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia
Daniela Ivanova Panova University Clinic of Obstetrics and Gynecology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia
Beti Zafirova Ivanovska University Clinic of Obstetrics and Gynecology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

DOI: https://doi.org/10.2298/VSP170504158B

Keywords: polycystic ovary syndrome, cardiovascular diseases, risk factors, homocysteine, c-reactive protein

Abstract

Abstract

Background/Aim. The prevalence of metabolic disorders, obesity and insulin resistance in women with polycystic ovary syndrome (PCOS) occur early in life and places this group at risk of cardiovascular disease. Hyperhomocysteinemia and increased C-reactive protein (CRP) activity have an effect on promoting atherosclerosis. This study was designed to evaluate whether high sensitivity (hs-CRP) and homocysteine (Hcy) are elevated in PCOS and to elucidate their possible relation to obesity, insulin resistance, or metabolic changes usually present in women suffering from PCOS. Methods. Serum concentration of hs-CRP and plasma levels of Hcy were evaluated in 73 PCOS women and 43 healthy women, together with clinical, anthropometric and hormonal parameters. Results. The mean of body mass index (BMI), waist circumference (WC), waist to hip ratio and mean concentration of luteinizing hormone (LH), testosterone, androstenedione, free androgen index, fasting insulin, homeostatic model assessment of insulin resistance (HOMA- IR), hs-CRP and Hcy were significantly higher in PCOS women compared to age-matched healthy women. There was a positive correlation between hs-CRP and BMI, WC, insulin, triglycerides (p < 0.001) and significant negative correlation with LH, sex hormone binding protein (SHGB), HOMA-IR, high density lipoprotein cholesterol (HDL-C) (p < 0.001). The Hcy concentration had a significant negative correlation with HDL-C level (p < 0.05). The present study demonstrated increased mean concentration of Hcy in hs-CRP women with PCOS. Conclusion. Our results support the use of these biomarkers in the evaluation of potential risk for cardiovascular diseases and early prognosis and treatment implications.

References

REFERENCES

March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Da-vies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic crite-ria. Hum Reprod 2010; 25(2): 544–51.

Wijeyaratne CN, Dilini US, Balen AH. Ethnic-specific poly-cystic ovary syndrome: Epidemiology, significance and impli-cations. Expert Rev Endocrinol Metab 2013; 8(1): 71–9.

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. ESE PCOS Special Interest Group: The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur J Endocri-nol 2014; 171(4): P1–29.

Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phe-notype and prevalence of obesity in polycystic ovary syn-drome. J Clin Endocrinol Metab 2013; 98(6): E1088–96.

Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005; 58(2): 151–4.

Guleria AK, Syal SK, Kapoor A, Kumar S, Tiwari P, Dabadghao P. Cardiovascular disease risk in young Indian women with poly-cystic ovary syndrome. Gynecol Endocrinol 2014; 30(1): 26–9.

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and meta-bolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8: 41.

Hart R, Doherty DA. The potential implications of a PCOS di-agnosis on a woman's long-term health using data linkage. J Clin Endocrinol Metab 2015; 100(3): 911–9.

Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev 2012; 33(6): 981–1030.

Sathyapalan T, Atkin SL. Mediators of Inflammation in Poly-cystic Ovary Syndrome in Relation to Adiposity. Mediators Inflamm 2010; 2010: 758656.

Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tis-sue: An endocrine organ. Arch Med Sci 2013; 9(2): 191–200.

Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73(3): 613–21.

Obersby D, Chappell DC, Dunnett A, Tsiami AA. Plasma total homocysteine status of vegetarians compared with omnivores: A systematic review and meta-analysis. Br J Nutr 2013; 109(5): 785–94.

Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325(7374): 1202.

Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol 2013; 168(6): 5126–34.

Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifa-kis S, Iliodromiti S, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol 2012; 28(12): 974–8.

Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endo-crinol (Oxford) 2007; 66(3): 440–6.

DeBoer MD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: A need for screening tools to target interventions. Nutrition 2013; 29(2): 379–86.

Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011; 17(6): 741–60.

Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: A syste-matic review and meta analysis. Fertil Steril 2011; 95(3): 1048–58.e1–2.

González F. Inflammation in Polycystic Ovary Syndrome: Un-derpinning of insulin resistance and ovarian dysfunction. Ste-roids 2012; 77(4): 300–5.

Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. In-creased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril 2009; 91(1): 213–9.

Cho LW, Jayagopal V, Kilpatrick ES, Atkin SL. The Biological Variation of C-Reactive Protein in Polycystic Ovarian Syn-drome. Clin Chem 2005; 51(10): 1905–7.

Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007; 23(9): 505–10.

Kurt RK, Okyay AG, Hakverdi AU, Gungoren A, Dolapcioglu KS, Karateke A, et al. The effect of obesity on inflammatory mark-ers in patients with PCOS: A BMI-matched case-control study. Arch Gynecol Obstet 2014; 2(290): 315–9.

Güdücü N, Işçi H, Yiğiter AB, Dünder I. C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome. J Turk Ger Gynecol Assoc 2012; 13(4): 227–32.

Baldani DP, Skrgatic L, Cerne JZ, Oguic SK, Gersak BM, Gersak K. Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome. Mol Med Rep 2015; 11(5): 3941–7.

Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal 2011; 15(7): 1927–43.

Celik C, Bastu E, Abali R, Alpsoy S, Guzel EC, Aydemir B, et al. The relationship between copper, homocysteine and early vascular disease in lean women with polycystic ovary syn-drome. Gynecol Endocrinol 2013; 29(5): 488–91.

Morgante G, La MA, Setacci F, Setacci C, Petraglia F, De Leo V. The cardiovascular risk factor homocysteine is not elevated in young women with hyperandrogenism or hypoestrogenism. Gynecol Obstet Invest 2002; 53(4): 200–3.

Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003; 18(4): 721–7.

Kilic-Okman T, Guldiken S, Kucuk M. Relationship between ho-mocysteine and insulin resistance in women with polycystic ovary syndrome. Endocr J 2004; 51(5): 505–8.

Chen S, Wu P, Zhou L, Shen Y, Li Y, Song H. Relationship be-tween increase of serum homocysteine caused by smoking and oxidative damage in elderly patients with cardiovascular dis-ease. Int J Clin Exp Med 2015; 8(3): 4446–54